Fam-Trastuzumab Deruxtecan in HER2/Neu-Expressing Serous Endometrial Cancer
JCO Precis Oncol
.
2023 Aug:7:e2300063.
doi: 10.1200/PO.23.00063.
Authors
Peter G Rose
1
,
Johanna A Kelley
1
,
Myra Feldman
2
,
Kevin Krivanek
3
Affiliations
1
Section of Gynecologic Oncology, Women's Health Institute, Cleveland Clinic, Cleveland, OH.
2
Section of Abdominal Imaging, Imaging Institute, Cleveland Clinic, Cleveland, OH.
3
Department of Pharmacy, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH.
PMID:
37595181
DOI:
10.1200/PO.23.00063
No abstract available
MeSH terms
Endometrial Neoplasms* / drug therapy
Endometrial Neoplasms* / genetics
Female
Humans
Immunoconjugates*
Oncogenes
Trastuzumab / therapeutic use
Substances
trastuzumab deruxtecan
Immunoconjugates
Trastuzumab